Periodontal Diseases
Conditions
Keywords
galectin-3
Brief summary
The aim of this study is to assess the levels of galectin-3 in the GCF and saliva in patient with gingivitis and patient with stage III periodontitis.
Detailed description
The aim of this study is to assess the levels of galectin-3 in the GCF and saliva in patient with gingivitis and patient with stage III periodontitis. This study will be conducted in the Oral Medicine and Periodontology department, Faculty of Dentistry- Cairo University, Egypt. Patients will be selected from the outpatient clinic of the department of Oral Medicine and Periodontology, Faculty of Dentistry-Cairo University.
Interventions
DIAGNOSTIC_TESTGCF obtaining
GCF sample collection by Enzyme-Linked Immunosorbent Assay (ELISA)
DIAGNOSTIC_TESTsaliva obtaining
Saliva sample collection by Enzyme-Linked Immunosorbent Assay (ELISA)
Sponsors
Cairo University
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
1. For healthy group: individuals with less than 10% bleeding on probing area, having a probing depth less than 4mm and no loss of attachment were included in the study. 2. For the gingivitis group: individuals with 10% or more bleeding on probing area, having a probing depth of less than 4mm and no attachment loss. 3. For the periodontitis group that has not received periodontal treatment in the last 6 months 4. For the periodontitis group: individuals with 30% or more bleeding on probing area, at least 2 teeth not adjacent to each quarter jaw with a depth of 5 mm or more and 4 mm or more attachment loss, coronal 1/3 and more on radiography (horizontal and / or vertical) bone loss. 5. Presence of a minimum of 15 natural teeth.
Exclusion criteria
1. Individuals with any known systemic disease. 2. Pregnant and lactating women. 3. Individuals that received periodontal treatment within the last 6 months. 4. Individuals with a history of systemic antibiotics and anti-inflammatory drugs within the last 3 months. 5. Former or current smokers.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| galectin-3 in GCF | 24 hours after taking the clinical measurements at the first visit | The total amount of Galectin-3 in GCF |
| galectin-3 in saliva. | 24 hours after taking the clinical measurements at the first visit | The total amount of Galectin-3 in saliva |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pocket depth | 24 hours before taking GCF and salivary samples | in mm |
| Clinical attachment level | 24 hours before taking GCF and salivary samples | in mm |
| Bleeding on Probing | 24 hours before taking GCF and salivary samples | By gently probing the orifice of the gingival crevice, the periodontal probe will be inserted 1 to2 mm into the gingival sulcus starting at one interproximal area and moving to the other. If bleeding occurs within 10 seconds a positive finding is recorded. |
| Plaque Index | 24 hours before taking GCF and salivary samples | Scores: 0: No plaque 1. A film of plaque adhering to the free gingival margin and adjacent area of the tooth. The plaque may be seen insitu only after application of a disclosing solution or by using the probe on the tooth surface. 2. Moderate accumulation of soft deposit s within the gingival pocket, or the tooth and gingival margin, which can be seen with the naked eye. 3. Abundance of soft matter within the gingival pocket and/or on the tooth and gingival margin. |
Countries
Egypt
Outcome results
None listed